 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
Welcome To Cortical Cortical is a Melbourne based drug discovery and development company, which was formed in 2003 around the work of Professor Eric Morand and Dr Magdy Iskander of Monash University. Cortical is funded by leading biotech venture capital group GBS Venture Partners. Cortical's mission is to produce small-molecule solutions to therapeutic targets in inflammation, and commercialise these via research and development, and where appropriate via strategic partnership with pharmaceutical and biotechnology companies. Diseases as diverse as arthritis, lupus, atherosclerosis, psoriasis, asthma, multiple sclerosis and colitis are characterised by inflammation, and may be targeted with drugs from Cortical's R&D. Based in Melbourne, Australia's capital of biomedical research and biotechnology commercialisation, Cortical operates its R&D in fully complemented laboratories within the Monash research precincts.
|